Integrating leptin and cAMP signalling pathways in triple-negative breast cancer cells.

"Triple-negative breast cancers are characterised. by an aggressive phenotype, are often found in younger. women and have been associated with poor prognosis.. Because triple-negative breast cancer patients are. unresponsive to current targeted therapies and other. treatment options are only partially effective, new. pharmacological approaches are warranted. The obesitylinked. adipokine, leptin, is a well known mitogen\/survival. factor in breast cancer cells and several studies have. addressed its role in breast cancer. Surprisingly, recent in. vitro studies have shown that leptin enhances the antiproliferative. effects of cAMP elevation in triple-negative. breast cancer cells by apoptosis induction. In the current. review, we discuss on the role of cAMP as a growth. suppressor and of leptin as a growth promoting factor in. breast cancer cells and we will focus on the molecular. pathways involved in the antiproliferative interaction. between leptin and cAMP elevation. The rationale for the. possible development of a simple, cheap and innovative. approach for therapeutic intervention in triple-negative. breast cancer, based on the use of cAMP elevating drugs at. tolerable doses, will be discussed."